2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Mateos, MV, Puig, N. Accelerating Myeloma Drug Development: Will Minimal Residual Disease Replace Progression-Free Survival as an Intermediate Surrogate End Point?. J CLIN ONCOL 43 -. 10 abr 2025. . . F.I.:42,100 [doi:10.1200/JCO-25-00048]
Zugas, Ines, Tormo-Ratera, Marta, Oliver-Caldes, Aina, Soler-Perromat, Juan Carlos, Gonzalez-Calle, Veronica, Moreno, David F., Cabanas, Valentin, Lopez-Munoz, Nieves, Bartolome-Solanas, Alvaro, Espanol-Rego, Marta, Reguera-Ortega, Juan Luis, Rosinol, Laura, Lopez-Corral, Lucia, Tovar, Natalia, Rodriguez-Lobato, Luis Gerardo, Perez, Rosa Maria Alvarez, Varea, Sara, Olesti, Eulalia, Gomez-Grande, Adolfo, Frutos, Laura, Tamayo, Pilar, Juan, Manel, Moraleda, Jose M., Urbano-Ispizua, Alvaro, Gonzalez-Navarro, E. Azucena, Martinez-Lopez, Joaquin, Mateos, Maria-Victoria, Tomas, Xavier, Setoain, Xavier, de Larrea, Carlos Fernandez. Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma. BLOOD ADV 9 571-582. 11 feb 2025. . . F.I.:7,400 [doi:10.1182/bloodadvances.2024014360]
Lasa, Marta, Notarfranchi, Laura, Agullo, Cristina, Gonzalez, Carmen, Castro, Sergio, Perez, Jose J., Burgos, Leire, Guerrero, Camila, Calasanz, Maria Jose, Flores-Montero, Juan, Oriol, Albert, Bargay, Joan, Rios, Rafael, Cabanas, Valentin, Cabrera, Carmen, Martinez-Martinez, Rafael, Encinas, Cristina, De Arriba, Felipe, Hernandez, Miguel-Teodoro, Palomera, Luis, Orfao, Alberto, Martinez-Lopez, Joaquin, Mateos, Maria-Victoria, San-Miguel, Jesus, Lahuerta, Juan Jose, Rosinol, Laura, Blade, Joan, Cedena, Maria Teresa, Puig, Noemi, Paiva, Bruno. Minimally Invasive Assessment of Peripheral Residual Disease During Maintenance or Observation in Transplant-Eligible Patients With Multiple Myeloma. J CLIN ONCOL 43 -. 10 ene 2025. . . F.I.:42,100 [doi:10.1200/JCO.24.00635]
Cohen, Yael C., Magen, Hila, Gatt, Moshe, Sebag, Michael, Kim, Kihyun, Min, Chang-Ki, Ocio, Enrique M., Yoon, Sung-Soo, Chu, Michael P., Rodriguez-Otero, Paula, Avivi, Irit, Quijano Carde, Natalia A., Kumar, Ashwini, Krevvata, Maria, Peterson, Michelle R., Di Scala, Lilla, Scott, Emma, Hilder, Brandi, Vanak, Jill, Banerjee, Arnob, Oriol, Albert, Morillo, Daniel, Mateos, Maria-Victoria. Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma. NEW ENGL J MED 392 138-149. 9 ene 2025. . . F.I.:96,200 [doi:10.1056/NEJMoa2406536]
Zabaleta, A, Puig, N, Cedena, MT, Oliver-Caldes, A, Perez, JJ, Moreno, C, Tamariz-Amador, LE, Rodriguez-Otero, P, Prosper, F, Gonzalez-Calle, V, López-Corral, L, Rey-Búa, B, Puertas, B, Mirás, F, Sánchez-Pina, J, López-Muñoz, N, Juan, ME, González-Navarro, E, Urbano, A, de Larrea, C, Blade, J, Lahuerta, JJ, Martinez-Lopez, J, Mateos, MV, San Miguel, JF, Paiva, B. Clinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T-cell redirecting immunotherapy. AM J HEMATOL 100 93-102. 1 ene 2025. 1 nov 2024. . F.I.:10,100 [doi:10.1002/ajh.27526]